Identification of fluid biomarkers for progressive supranuclear palsy (PSP) is critical to enhance therapeutic development. We implemented unbiased DNA aptamer (SOMAmer) proteomics to identify novel CSF PSP biomarkers.

Bookmark

CSF Proteomics in Patients With Progressive Supranuclear Palsy | Synapse

Cite This Study

Wise et al. (Wed,) studied this question.

synapsesocial.com/papers/68e616d2b6db6435875a9f07 https://doi.org/https://doi.org/10.1212/wnl.0000000000209585

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults2019 · 9 citations
2Concomitant pathologies among a spectrum of parkinsonian disorders

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults2019 · 9 citations
2Concomitant pathologies among a spectrum of parkinsonian disorders

2014 · 163 citations

3Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration2013 · 252 citations

4Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria2017 · 2,333 citations

5Reduced frequency of T lymphocytes expressing CTLA-4 in frontotemporal dementia compared to Alzheimer's disease2013 · 21 citations